161 related articles for article (PubMed ID: 24562448)
1. Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051).
Lockhart AC; Reed CE; Decker PA; Meyers BF; Ferguson MK; Oeltjen AR; Putnam JB; Cassivi SD; Montero AJ; Schefter TE;
Ann Oncol; 2014 May; 25(5):1039-44. PubMed ID: 24562448
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Choong NW; Mauer AM; Haraf DC; Ferguson MK; Sandler AB; Kesler KA; Fishkin PA; Ansari RH; Wade J; Krauss SA; Sciortino DF; Posner MC; Kocherginsky M; Hoffman PC; Szeto L; Vokes EE
Med Oncol; 2011 Dec; 28 Suppl 1():S152-61. PubMed ID: 20730572
[TBL] [Abstract][Full Text] [Related]
4. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.
Moehler M; Gockel I; Roessler HP; Arnold D; Trarbach T; Thomaidis T; Klautke G; Rödel C; Brenner B; Lang H; Galle PR; Schimanski CC; Schmidberger H
BMC Cancer; 2013 Feb; 13():75. PubMed ID: 23394629
[TBL] [Abstract][Full Text] [Related]
5. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02).
Ruhstaller T; Widmer L; Schuller JC; Roth A; Hess V; Mingrone W; von Moos R; Borner M; Pestalozzi BC; BalmerMajno S; Köberle D; Terraciano L; Schnider A; Bodis S; Popescu R;
Ann Oncol; 2009 Sep; 20(9):1522-1528. PubMed ID: 19465425
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
[TBL] [Abstract][Full Text] [Related]
9. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
10. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Tebbutt NC; Price TJ; Ferraro DA; Wong N; Veillard AS; Hall M; Sjoquist KM; Pavlakis N; Strickland A; Varma SC; Cooray P; Young R; Underhill C; Shannon JA; Ganju V; Gebski V
Br J Cancer; 2016 Mar; 114(5):505-9. PubMed ID: 26867157
[TBL] [Abstract][Full Text] [Related]
14. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
Hamai Y; Hihara J; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
Ann Thorac Surg; 2015 Jun; 99(6):1887-93. PubMed ID: 25912745
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
17. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
Pera M; Gallego R; Montagut C; Martín-Richard M; Iglesias M; Conill C; Reig A; Balagué C; Pétriz L; Momblan D; Bellmunt J; Maurel J
Ann Oncol; 2012 Mar; 23(3):664-670. PubMed ID: 21652581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
